CipherBio is the global community and knowledge hub for life sciences professionals.

81 Digital Therapeutics Companies Received $3.1 Billion From 302 Investors

CipherBio Data TeamSeptember 29, 2021

Digital therapeutics are quickly rising in popularity, with the advancement of technology such as artificial intelligence and machine learning. Digital therapeutics are defined as clinically evaluated software systems used as medical interventions to treat or manage medical conditions. The digital therapeutics field includes Software as a Medical Device (SAMD) which performs as a medical device […] READ MORE

immuno-oncology

183 Immuno-Oncology Companies Raised $46 Billion

CipherBio Data TeamSeptember 14, 2021

Attempts to harness the immune system to fight cancer date back to the late 1800s. It has been less than 40 years since the first of these immuno-oncology therapies demonstrated success and obtained approval. Since then, nearly 40 cancer immunotherapies have received FDA approval. These approved treatments fall into five categories of immunotherapy: cell-based, immunomodulators […] READ MORE

$18 Billion Invested in 135 Cell Therapy Companies

CipherBio Data TeamAugust 18, 2021

Cell therapy was born in the 1930s when Paul Niehans earned the title of “father of cell therapy” by injecting the cells of animal organs into patients with numerous conditions including cancer. Although cell therapy was discovered nearly a century ago, new advances and techniques have caused a large increase in life science cell therapy […] READ MORE

64 Microbiome Biotechs Raise $1.6 Billion in Investments

CipherBio Data TeamJuly 26, 2021

In the last decade, a relatively uncharted field exploded in the life science industry, provoking Forbes to declare the 2010s “The Decade of the Microbiome.” This expansion in the microbiome field was largely due to The National Institutes of Health’s “The Human Microbiome Project,” ending in 2016, which provided significant evidence for the association between […] READ MORE

eye diseases

Life Science Companies Step Up the Fight Against Vision Loss by raising $13B+ from over 300 investors

CipherBio Data TeamJuly 20, 2021

The number of adults at risk for vision loss grew substantially from 2002-2017, from 65 million to 93 million. According to the CDC, more than 4.2 million Americans suffer from low vision or blindness. The leading causes of vision loss are age-related eye diseases such as age-related macular degeneration (AMD), cataract, diabetic retinopathy, and glaucoma. […] READ MORE

Export Investors and Companies by Location

CipherBio PRO Users Explore Hot Markets and Deal Activity by City, State and Country

CipherBio Data TeamJuly 12, 2021

You dove into the CipherBio ecosystem, discovering companies and investors rooted in life science. You also asked for something new: location specific lists for export. We are happy to announce we’ve delivered on that request and those location pages are now live and ready for you to explore, just as you have been with company […] READ MORE

Record Breaking Numbers in Life Science IPOs

CipherBio Data TeamJuly 6, 2021

The number of biotechs entering the public markets is at an all-time high, with 2020 breaking all biotech IPO records, and 2021 on track to rival these numbers. The latest CipherBio PRO data insight showcases these groundbreaking numbers. From 2019 to Q2 2021 over 220 companies went public with deals totaling $40+ Billion in IPO […] READ MORE

SVB Clients Receive Preferred Discounts on CipherBio PRO With Access to $580B+ in Global Life Science VC Funding

CipherBio Data TeamJune 28, 2021

SVB Financial Group built and funded CipherBio to help Founders and CEOs raise capital. CipherBio PRO provides companies & VCs with access to $580B+ in global life science VC funding activity. Most funding databases cost $5K to $15K per seat for an annual subscription. CipherBio is aware that Pre A companies cannot afford $5K+ per […] READ MORE

Life Science M&A Focused on Immunotherapy and Antibodies

CipherBio Data TeamJune 21, 2021

The life science M&A trend is not slowing down. Nearly $30B has been poured into life science acquisitions year to date through May 2021. Not only does the CipherBio PRO M&A Insights reveal the top deals in 2019-2021, acquirers and investors, but it also highlights the data and scientific work behind these billion-dollar deals. READ MORE

Download $520B+ of Funding Data to Excel to Build Investor and Company Lists From CipherBio PRO

Matt GibbsMay 26, 2021

We listened to our CipherBio PRO VC and CEO users and increased access to download $520B of life science funding deals to Excel. As a former VC for 20 years and founder of CipherBio@svb, I get excited that CipherBio PRO investor and company lists help CEOs raise capital and support investors in sourcing deals. READ MORE

metabolic

CipherBio PRO Dives Into the Booming Metabolic Disorder Sector

CipherBio Data TeamMay 17, 2021

Here’s an energizing topic: metabolism. Metabolism is the essential and fundamental process your body performs to make energy from the food you eat. But when just one step along the complex metabolic process fails, the body retains either too much or too little of one of the many essential substances it needs to maintain optimal […] READ MORE

CRISPRgene therapy

NPR Has Its Eye on Landmark Gene-Editing Experiment to Restore Vision

CipherBio Data TeamMay 12, 2021

We’ve been watching advances in gene therapy that bring hope to those who suffer vision loss or blindness due to genetic conditions. And we’re not the only ones. This just in: NPR recently interviewed patients involved in a landmark study using a gene-editing technique called CRISPR. NPR is the first to interview these patients. READ MORE

Subscribe

Premium Investor Insights